{"prompt": "['If less than 16 patients stop treatment for 8 consecutive days due to safety', 'concerns, 16 new patients will be included (Step 4A).', 'If 16 or more patients stop treatment for at least 8 consecutive days due to', 'safety concerns, depending on the group imbalance, the DSMB may request', 'the lifting of the blind and inclusions may be discontinued (Step 4B). Total', 'number of patients included: 8 + 8 + 16 = 32.', 'STEP4 - Following inclusions, all centers', 'STEP 4A- Inclusion of 16 new patients, total number of patients included = 48', 'D', 'D', 'D', 'S', 'S', 'S', 'STEP 1', 'M', 'STEP 2', 'M', 'STEP 3', 'M', 'STEP 4', 'B', 'B', 'B', '1', '2', '3A', '3', 'inclusion', '2A', 'inclusion', '+24 patients', 'total: 8+16+24=48', '+16 patients', 'total : 8+16=24', '3B', 'inclusion', 'discontinuation', '4A', 'inclusion', '2B', 'Inclusion', '3C', '+16 patients', 'inclusion', 'inclusion', 'total: 8+8+16+16=48', '8 patients', '+8 patients', '+ 16 patients', 'total: 8+8=16', 'total: 8+8+16= 32', '4B', 'inclusion', '3D', 'discontinuation', 'inclusion', 'discontinuation', '2C', 'inclusion', 'discontunation', 'Figure 5: Inclusions flow chart', '3', 'Objectives', '3.1 Main objective', 'To evaluate, at 6 weeks after the end of the treatment, the efficacy of tacrolimus nasal', 'ointment on the duration of nosebleeds when administered for 6 weeks in patients with', 'HHT complicated by nosebleeds.', 'Page 27 of 64']['3.2 Secondary objectives', 'The secondary objectives are to evaluate:', '4. Tolerance of tacrolimus nasal administration for 6 weeks, throughout the study.', '5. Efficacy of the treatment on progress in the', 'clinical parameters:', '- Nosebleed duration,', '- Number of nosebleeds,', '- Number of transfusions of red blood cells.', '-', 'Quality of life', '-', 'ESS = Epistaxis Severity Score', 'biological parameters: hemoglobin and serum ferritin concentrations', 'These parameters will be evaluated at the end of the 6 weeks of treatment (V2)', 'and at the end of 6 weeks of follow-up (V3).', '6. Systemic absorption after nasal administration.', '4', 'Methodology', '4.1 Outline of the experiment', 'This is a multicenter, randomized study carried out in double blind. For all patients,', \"monitoring will be for 12 weeks (6 weeks' treatment + 6 weeks' follow-up).\", '4.1.1', 'Monitoring the patients', 'The tacrolimus ointment will be delivered at the centers participating in the study during', 'the first visit after verifying the inclusion criteria. A phone call is scheduled on day 31,', 'i.e. 30 days after the beginning of the treatment, to monitor the safety of the treatment.', 'Patients will have two medical visits: at the end of the treatment and after 6 weeks of', 'follow-up.', 'A scientific committee and an independent monitoring committee will be set up (see', 'paragraph 12.1 & 12.2).', 'A specific management procedure is envisaged for each expected complication (see', 'paragraph 7.3).', '4.1.2 Patient selection', 'Patients in the HHT network will thus be informed of the study in progress during a', 'standard ENT consultation or in the Reference Center or Skill Center.', 'Patients will be included (the consent form will be signed) on the day of the treatment', 'is prescribed.', 'Subjects will be attributed a number in relation to their chronological inclusion.', '4.1.3', 'Duration of the study', 'The duration of the inclusion period will be maximum 18 months.', 'Page 28 of 64'][\"The duration of participation per patient will be 12 weeks (6 weeks' treatment + 6\", \"weeks' of follow-up).\", 'The total duration of the study will thus be maximum 21 months.', 'Year 1', 'Year 2', 'M1', 'M2 M3 M4 M5 M6 M7 M8 M9 M10 11M M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22', '1 - Inclusion', 'D31', '81', 'D85', 'Follow up', '2', 'Monitoring', 'M', 'D31', '2A', '16 i', 'D85', '2', 'M', 'D31', '3A', '24 1', 'D85', '2', 'DSMB 2', 'M', 'N=48 (8+16+24)', 'Analysis', '3B', '8', 'STOP N=24 (8+16)', 'D31', '2B', '81', 'D85', '2', 'DSMB 1', 'M', 'D31', '3C', 'C', '16 1', 'D85', '2', 'M', 'D31', '4A', 'C', '16 1', 'D85', 'DSMB 2', '2', 'DSMB 3', 'M', 'N=48 (8+8+16+16)', 'Analysis', '4B', '8', 'STOP N=32 (8+8+16)', 'N=number of', '3D', 'patients', 'STOP N=16 (8+8)', 'included', '2C', '2', 'STOP N=8', 'Figure 6: Schedule', '4.2 Patients', '4.2.1 Recruitment and feasibility', 'Aspects to ensure the feasibility of the project', '- Network coordinated by the reference center (over 2000 patients followed', 'regularly). The cohort of patients followed for HHT in the Lyon reference center', 'is around 1,000 patients. At the national level, more than 2,000 patient files are', 'currently included in the database. Of these patients, at least 25% present with', 'nosebleeds that justify ENT management.', '-', 'The complication targeted by the treatment (epistaxis) is frequent, present in', '95% of patients over the age of 50.', '- Previous studies conducted by the Reference center, including Metafore', 'published in 2012,\u00b9 Ellipse published in 201465 and Alegori published in 201663', \"- The support of the patients' association (AMRO) and the high expectations of\", 'the patients.', '4.2.2 Number of patients', 'We intend to randomize 48 patients.', 'Page 29 of 64']\n\n###\n\n", "completion": "END"}